NCT03954704: Study of GS-1423 in Participants With Advanced Solid Tumors

NCT03954704
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known untreated unstable central nervous system metastasis
https://ClinicalTrials.gov/show/NCT03954704

Comments are closed.

Up ↑